Ikena Oncology, Inc. Company Profile & Data: stocks, market cap, financials, digital and more

                        
Company
Ikena Oncology, Inc.Headquarters: Boston, 
                        MA, United States
                    
Employees: 67
CEO: Dr. Mark  Manfredi Ph.D.

                                    NASDAQ: IKNA
                                
                                            -5.83%
                                            
Market Cap$82.0 Million

                        USD as of Jan. 1, 2025
                    
                            Market Cap History

Ikena Oncology, Inc. Categories

United States Healthcare Biotechnology
United States Healthcare United States Biotechnology

Ikena Oncology, Inc. market capitalization over time

Evolution of Ikena Oncology, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Ikena Oncology, Inc.

Top Competitors by Market Capitalization

Industry: Biotechnology

Company	Market Cap (USD)
Novo Nordisk	$622.07 B
Vertex Pharmaceuticals Incorporated	$113.24 B
CSL Limited	$95.75 B
Regeneron Pharmaceuticals, Inc.	$76.33 B
Marinomed Biotech AG	$56.13 B

Sector:

Company	Market Cap (USD)
Lilly	$689.42 B
Novo Nordisk	$622.07 B
UnitedHealth Group	$487.54 B
Johnson & Johnson	$353.05 B
AbbVie	$301.60 B

Detailed Description

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Top 1-year algo backtest: +327.04%

$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Financials

Last Financial Reports Date	Dec. 31, 2023
Revenue TTM	$9.2 M
EBITDA	$-74,397,000
Gross Profit TTM	$0
Profit Margin	0.00%
Operating Margin	-3324.43%
Quarterly Revenue Growth	-87.90%